SAN DIEGO--(BUSINESS WIRE)-- Cardea Bio Inc, a Tech+Bio company integrating molecular biology with semiconductor electronics, appoints Kelly Huang, Ph.D. as Chief Operating Officer (COO). Dr. Huang brings more than 25 years of medical device, health IT, and consumer health experience to Cardea.

Spearheading a new class of life science signal detection technology, Cardea’s proprietary Cardean Transistors™ employ graphene to link the digital world of semiconductor microelectronics directly to molecular biology, thereby enabling the development of a new generation of highly sensitive diagnostics, research tools, and other biosensor-integrated applications for a myriad of industries. In this newly created role, Dr. Huang will oversee business operations, including manufacturing and commercial scaling, to meet the needs of Cardea’s growing collection of partners and to reach new markets.

“I am excited to join the preeminent team at Cardea, a disruptive platform company with the talent, technology, and mission to change the future,” says Dr. Huang. “I believe Cardea’s graphene-based, biology-gated transistor technology will solve some of the world’s most pressing problems, and I look forward to working with the team to advance novel innovations into commercial applications.”

Part of Dr. Huang’s responsibilities at Cardea will be to build upon their expansive product portfolio, including their CRISPR-Chip, SNP-Chip, and EV-Chip, as well as chips they’re developing in partnership with biotechnology companies such as Scentian Bio and a number of very large, yet undisclosed, partners.

“Dr. Huang represents the kind of formidable talent, experience, values and diverse set of capabilities we’re investing in for the next stage of Cardea,” states Michael Heltzen, CEO of Cardea Bio. “The hire of Dr. Huang reflects our focus on scaling and commercializing Cardea’s proven applications, in close collaboration with our world-class partners.”

Dr. Huang brings more than 25 years of diverse executive and operational experience in medical devices, services, health IT, and consumer health to Cardea. Prior to Cardea, Dr. Huang held the positions of COO and President of Nutri-Therapeutic at L-Nutra, where he supported a significant increase in sales and funding through the COVID-19 pandemic. Before this, he was CEO, President, and Board Director for Obalon Therapeutics, a publicly traded medical device company commercializing novel weight-loss technologies including delivery systems integrating electrical, mechanical, and sensing technologies. Through the previous decade, he held several management and executive roles leading development of multiple new technologies and commercial launches at Nestle Skin Health, Endo Health Solutions, and the Johnson & Johnson family of companies.

About Cardea Bio

Cardea is linking computers to the live molecular signals running biology. Its multi-omics technology consists of a Tech+Bio Infrastructure (hardware, software and wetware) and Chipsets manufactured with proprietary graphene-based, biology-gated transistors, called Cardean Transistors™.

Cardean Transistors leverage graphene, a nanomaterial that is biocompatible and a near perfect conductor as it is only one atom thick, in contrast to the common semiconductor material, silicon. Cardea thereby gains a signal resolution high enough to listen into molecular signals in a manner that replaces optical and static measurements with interactive live streams of multi-omic signals and analyses.

Cardea is on a long-term mission they call “Linking up to Life” to empower its partners with Tech+Bio solutions that make significant positive impacts on the world via innovative applications that are “Powered by Cardea.” For more information about Cardea Bio Inc. visit www.cardeabio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005014/en/